Q-omics provides the consensus-scored OFD1 profile across patient tissues and cancer cell-line models. OFD1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, OFD1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, OFD1 RNA expression shows 20,582 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where OFD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OFD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OFD1 survival associations across molecular data types. OFD1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (10) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OFD1 RNA expression–survival associations across cancer types. High OFD1 expression shows unfavorable associations in LIHC, KICH and LGG, but favorable associations in BLCA, SKCM and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for OFD1 RNA expression.
This table summarizes OFD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OFD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OFD1 shows higher tumor expression in KIRC, LIHC, STAD, CHOL, COAD and BLCA. The KIRC box plot shows higher OFD1 RNA expression in tumor versus normal tissue (log2 FC = +0.465, t-test p < 0.001).
This table shows molecular features associated with OFD1 in patient tissues and cancer cell lines. In patient samples, OFD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, OFD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
